Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses
Kymera Therapeutics Inc KYMR
$79.67
▼ -3.09%
($-2.54)
Open
$82.41
Prev Close
$82.21
Day Range
$79.07 – $83.41
52W Range
$28.06 – $103.00
Market Cap
$6.76B
Beta
2.06
EPS (TTM)
$-3.57
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-08-21 |
| Shares Out. | 81,640,000 |
| Website | kymeratx.com/ ↗ |
| Phone | 13026587581 |
Kymera Therapeutics Inc is a publicly traded company under the ticker symbol KYMR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
29 analysts (2026-05-01)
📰 Latest News for KYMR
Kymera Therapeutics Announces Presentations On Results From KT-621 Clinical Trial At Annual Meetings May 13-16
Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Transcript : Kymera Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 09
Canaccord Genuity Initiates Coverage On Kymera Therapeutics with Buy Rating, Announces Price Target of $106
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
Kymera Therapeutics Presented New Preclinical Data For KT-579 Demonstrating Disease-modifying Activity In An Inflammatory Bowel Disease Model, KT-579 Phase 1 Healthy Volunteer Trial Ongoing, With Data Expected In 2H26
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week